Challenges and pitfalls in the application of diethyldithiocarbamate derivatization for LC analysis of cisplatin and oxaliplatin, as well as the suitability of this method for different biological matrices with implications for use in routine practice have been identified. The LC of platinum drugs presents a significant challenge. They are polar compounds with poor retention on reverse phase packings. Cisplatin also exhibits poor absorption in UV and ionization in mass spectrometry. Therefore, we developed and optimized a derivatization approach for the LC analysis of total platinum in plasma, plasma ultrafiltrate, peritoneal fluid, and urine. Derivatization in urine proved to be difficult due to the complexity of the matrix, and extended testing was required. Our results highlight the important issues affecting the efficiency, reliability, and suitability of platinum drug derivatization. Although precolumn derivatization is less selective than its postcolumn counterpart, the application of precolumn derivatization is a simple, rapid, and universal approach for the determination of platinum drugs by HPLC. One of its major advantages is that it allows a more affordable analysis using UV detection without the need for additional high-end instrumentation such as a MS detector.

Department of Analytical Chemistry Faculty of Pharmacy in Hradec Králové Charles University Hradec Králové Czech Republic

Department of Clinical Biochemistry and Diagnostics University Hospital Hradec Králové Hradec Králové Czech Republic

Department of Oncology and Radiotherapy University Hospital Hradec Králové Hradec Králové Czech Republic

Department of Oncology Faculty of Medicine and Dentistry Palacký University Olomouc Czech Republic

Zobrazit více v PubMed

Mladenova E, Karadjova I, Tsalev DL. Solid-phase extraction in the determination of gold, palladium, and platinum: Sample preparation. J Sep Sci. 2012;35:1249-65.

Balcerzak M. Methods for the determination of platinum group elements in environmental and biological materials: A review. Crit. Rev. Anal. Chem. 2011;41:214-35.

Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nat. Rev. Cancer. 2021;21:37-50.

Dilruba S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother. Pharmacol. 2016;77:1103-24.

Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018;47:6645-53.

Ventura G, Calvano CD, Losito I, Bianco G, Pascale R, Palmisano F, et al. Effect of pH and mobile phase additives on the chromatographic behaviour of an amide-embedded stationary phase: Cyanocobalamin and its diaminemonochloro-platinum(II) conjugate as a case study. J. Sep. Sci. 2019;42:1155-62.

Voelker T, Meng M. in: Li W, Zhang J, Tse FLS, editors. Handbook of LC-MS bioanalysis. Hoboken, NJ, USA: John Wiley & Sons Inc.; 2013. p. 629-37.

Raudenska M, Balvan J, Fojtu M, Gumulec J, Masarik M. Unexpected therapeutic effects of cisplatin. Metallomics. 2019;11:1182-99.

Lemma T, Mandal R, Li X-F, Pawliszyn J. Investigation of interaction between human hemoglobin A0 and platinum anticancer drugs by capillary isoelectric focusing with whole column imaging detection. J. Sep. Sci. 2008;31:1803-9.

Hemström P, Nygren Y, Björn E, Irgum K. Alternative organic solvents for HILIC separation of cisplatin species with on-line ICP-MS detection. J. Sep. Sci. 2008;31:599-603.

Xie F, Colin P, Van Bocxlaer J. Zwitterionic hydrophilic interaction liquid chromatography-tandem mass spectrometry with HybridSPE-precipitation for the determination of intact cisplatin in human plasma. Talanta. 2017;174:171-8.

Bell DN, Liu JJ, Tingle MD, McKeage MJ. Specific determination of intact cisplatin and monohydrated cisplatin in human plasma and culture medium ultrafiltrates using HPLC on-line with inductively coupled plasma mass spectrometry. J. Chromatogr. B. 2006;837:29-34.

Verschraagen M, van der Born K, Zwiers THU, van der Vijgh WJF. Simultaneous determination of intact cisplatin and its metabolite monohydrated cisplatin in human plasma. J. Chromatogr. B. 2002;772:273-81.

Andersson A, Fagerberg J, Lewensohn R, Ehrsson H. Pharmacokinetics of cisplatin and its monohydrated complex in humans. J. Pharm. Sci. 1996;85:824-7.

Hann S, Koellensperger G, Stefánka Zs, Stingeder G, Fürhacker M, Buchberger W, et al. Application of HPLC-ICP-MS to speciation of cisplatin and its degradation products in water containing different chloride concentrations and in human urine. J Anal Spectrom. 2003;18:1391-5.

Xie F, Pieter C, Jan VB. Electrospray ionization mass spectrometry for the hydrolysis complexes of cisplatin: implications for the hydrolysis process of platinum complexes: Electrospray ionization mass spectrometry for the hydrolysis complexes of cisplatin. J. Mass Spectrom. 2017;52:434-41.

Lemoine L, Thijssen E, Noben J-P, Adriaensens P, Carleer R, Speeten KV. A validated inductively coupled plasma mass spectrometry (ICP-MS) method for the quantification of total platinum content in plasma, plasma ultrafiltrate, urine and peritoneal fluid. J. Pharm. Biomed. Anal. 2018;152:39-46.

Rudnev AV, Aleksenko SS, Semenova O, Hartinger CG, Timerbaev AR, Keppler BK. Determination of binding constants and stoichiometries for platinum anticancer drugs and serum transport proteins by capillary electrophoresis using the Hummel-Dreyer method. J. Sep. Sci. 2005;28:121-7.

Ehrsson H, Wallin I, Yachnin J. Pharmacokinetics of oxaliplatin in humans. Med. Oncol. Northwood Lond. Engl. 2002;19:261-6.

Falta T, Koellensperger G, Standler A, Buchberger W, Mader RM, Hann S. Quantification of cisplatin, carboplatin and oxaliplatin in spiked human plasma samples by ICP-SFMS and hydrophilic interaction liquid chromatography (HILIC) combined with ICP-MS detection. J. Anal. At. Spectrom. 2009;24:1336.

Brouwers EEM, Tibben MM, Rosing H, Hillebrand MJX, Joerger M, Schellens JHM, et al. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. J. Mass Spectrom. 2006;41:1186-94.

Martinčič A, Cemazar M, Sersa G, Kovač V, Milačič R, Ščančar J. A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection. Talanta. 2013;116:141-8.

Martín J, Camacho-Muñoz D, Santos JL, Aparicio I, Alonso E. Simultaneous determination of a selected group of cytostatic drugs in water using high-performance liquid chromatography-triple-quadrupole mass spectrometry: Liquid Chromatography. J. Sep. Sci. 2011;34:3166-77.

Brouwers EEM, Tibben MM, Joerger M, van Tellingen O, Rosing H, Schellens JHM, et al. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. Anal. Bioanal. Chem. 2005;382:1484-90.

de Jong LAW, Elekonawo FMK, Lambert M, de Gooyer JM, Verheul HMW, Burger DM, et al. Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study. Cancer Chemother. Pharmacol. 2020;86:141-50.

Chalret du Rieu Q, White-Koning M, Picaud L, Lochon I, Marsili S, Gladieff L, et al. Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: Correlation between oxaliplatin exposure and thrombocytopenia. Cancer Chemother. Pharmacol. 2014;74:571-82.

Tang C, Li C, Tang C, Zhan W, Zheng H, Peng X. Quantitative determination of platinum derived from cisplatin in human plasma ultrafiltrate using derivatization with diethyldithiocarbamate and liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Anal. Methods. 2013;5:7117.

Hrušková H, Voráčová I, Řemínek R, Foret F. Current applications of capillary electrophoresis-mass spectrometry for the analysis of biologically important analytes in urine (2017 to mid-2021): A review. J. Sep. Sci. 2022;45:305-24.

Zhang W, Seymour L, Chen EX. Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. 2008;876:277-82.

Ito H, Yamaguchi H, Fujikawa A, Tanaka N, Furugen A, Miyamori K, et al. A full validated hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the quantification of oxaliplatin in human plasma ultrafiltrates. J. Pharm. Biomed. Anal. 2012;71:99-103.

Zhang Q, Yang F-Q, Ge L, Hu Y-J, Xia Z-N. Recent applications of hydrophilic interaction liquid chromatography in pharmaceutical analysis. J. Sep. Sci. 2017;40:49-80.

Metabocard for Cisplatin (HMDB0014656). Hum. Metabolome Database HttpshmdbcametabolitesHMDB0014656 n.d.

Arenas M, Martín J, Santos JL, Aparicio I, Fernández-Sanfrancisco O, Alonso E. Comparison of different techniques for the determination of platinized cytostatic drugs in urine samples. Molecules. 2022;27:8139.

Yaroshenko DV, Grigoriev AV, Sidorova AA, Kartsova LA. Determination of cisplatin in blood plasma by liquid chromatography with mass spectrometry detection. J. Anal. Chem. 2013;68:156-60.

Gerina-Berzina A, Hasnere S, Kolesovs A, Umbrashko S, Muceniece R, Nakurte I. Determination of cisplatin in human blood plasma and urine using liquid chromatography-mass spectrometry for oncological patients with a variety of fatty tissue mass for prediction of toxicity. Exp. Oncol. 2017;39(2):124-30.

Kaushik KH, Sripuram VK, Bedada S, Reddy NY, Priyadarshini GI, Devarakonda KR. A simple and sensitive validated HPLC method for quantitative determination of cisplatin in human plasma. Clin. Res. Regul. Aff. 2010;27:1-6.

Shaik AN, Altomare DA, Lesko LJ, Trame MN. Development and validation of a LC-MS/MS assay for quantification of cisplatin in rat plasma and urine. J. Chromatogr. B. 2016;1046:243-9.

Khuhawar M, Arain G. Liquid chromatographic determination of cis-platin as platinum(II) in pharmaceutical preparation, serum and urine samples of cancer patients. Talanta. 2005;66:34-9.

Ariöz F, Yalçin G, Dölen E. Determination of cisplatin, transplatin and amminetri-chloroplatinate by high performance liquid chromatography in one run using 4-methyl-2-thiouracil as derivatizing agent. Chromatographia. 1999;49:562-6.

Lin H, Huang ZJ, Hu Q, Yang G, Zhang G. Determination of palladium, platinum, and rhodium by HPLC with online column enrichment using 4-carboxylphenyl-thiorhodanine as a precolumn derivatization reagent. J. Anal. Chem. 2007;62:58-62.

Hu Q, Yang X, Huang Z, Chen J, Yang G. Simultaneous determination of palladium, platinum, rhodium and gold by on-line solid phase extraction and high performance liquid chromatography with 5-(2-hydroxy-5-nitrophenylazo)thiorhodanine as pre-column derivatization regents. J. Chromatogr. A. 2005;1094:77-82.

Pierre PV, Wallin I, Eksborg S, Ehrsson H. Quantitative liquid chromatographic determination of intact cisplatin in blood with microwave-assisted post-column derivatization and UV detection. J. Pharm. Biomed. Anal. 2011;56:126-30.

Andersson A, Ehrsson H. Determination of cisplatin and cis-diammineaquachloroplatinum(II) ion by liquid chromatography using post-column derivatization with diethyldithiocarbamate. J. Chromatogr. B. Biomed. Sci. App. 1994;652:203-10.

Krčmová L, Solichova D, Melichar B, Kasparova M, Plisek J, Sobotka L, et al. Determination of neopterin, kynurenine, tryptophan and creatinine in human serum by high throuput HPLC. Talanta. 2011;85:1466-71.

Lopez-Flores A, Jurado R, Garcia-Lopez P. A high-performance liquid chromatographic assay for determination of cisplatin in plasma, cancer cell, and tumor samples. J. Pharmacol. Toxicol. Methods. 2005;52:366-72.

Otsuki Y, Kotani A, Kusu F. Capillary liquid chromatography with UV detection using N,N-diethyl dithiocarbamate for determining platinum-based antitumor drugs in plasma. Chem. Pharm. Bull. (Tokyo). 2012;60:665-9.

Augey V, Cociglio M, Galtier M, Yearoo R, Pinsani V, Bressolle F. High-performance liquid chromatographic determination of cis-dichlorodiammineplatinum(II) in plasma ultrafiltrate. J. Pharm. Biomed. Anal. 1995;13:1173-8.

Brouwers EE, Huitema AD, Beijnen JH, Schellens JH. Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin. Pharmacol. 2008;8:7.

Ma J, Stoter G, Verweij J, Schellens JHM. Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations. Cancer Chemother. Pharmacol. 1996;38:391-4.

Goel R, Andrews PA, Pfeifle CE, Abramson IS, Kirmani S, Howell SB. Comparison of the pharmacokinetics of ultrafilterable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy. Eur. J. Cancer Clin. Oncol. 1990;26:21-7.

Mikkelsen MS, Blaakaer J, Petersen LK, Schleiss LG, Iversen LH. Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer. Pleura Peritoneum. 2020;5:20200137.

Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin-A Sankai Gynecology Study Group (SGSG) study. Gynecol. Oncol. 2005;99:591-6.

Royer B, Delroeux D, Guardiola E, Combe M, Hoizey G, Montange D, et al. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer. Cancer Chemother. Pharmacol. 2008;61:415-21.

Tarn AC, Lapworth R. Biochemical analysis of ascitic (peritoneal) fluid: what should we measure? Ann. Clin. Biochem. 2010;47:397-407.

Witkamp AJ, de Bree E, Van Goethem R, Zoetmulder FAN. Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat. Rev. 2001;27:365-74.

Brücher BLDM, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y, et al. Peritoneal carcinomatosis: Cytoreductive surgery and hipec--overview and basics. Cancer Invest. 2012;30:209-24.

Clarkson MR, Brenner BM, Magee CN. Pocket companion to Brenner and Rector's: The kidney. Netherlands: Elsevier; 2011. p. 21-41.